Abstract Alterations in microRNA (miRNA) expression in postmortem brain tissue or peripheral blood have been linked to schizophrenia. Cerebrospinal fluid might provide an in vivo biomarker more directly reflecting functional changes in the brain. The goals of this study were to determine the feasibility of detecting miRNAs in cerebrospinal fluid and to compare miRNA levels in cerebrospinal fluid versus blood. Four healthy volunteers and four patients with psychotic disorders underwent a lumbar puncture and a blood draw. Expression of 378 validated miRNAs was assessed from each biofluid type for each subject using microarray technology. Five miRNAs were chosen for validation with quantitative polymerase chain reaction. A substantial number of miRNAs (n095) were exclusively or predominately detected in cerebrospinal fluid (CSF). Levels of 35 miRNAs detected in both CSF and blood samples in all subjects were poorly correlated. The investigation of miRNAs in CSF can help advance the understanding of psychiatric diseases and particularly schizophrenia.
Introduction
MicroRNAs (miRNAs) are small noncoding RNA fragments that are involved in post-transcriptional regulation of messenger RNAs. Due to their ability to simultaneously regulate the transcription of multiple mRNAs, miRNAs are appealing as potential biomarkers in the study of psychiatric diseases, where multiple mechanisms and pathways are likely implicated (Hunsberger et al. 2009 ).
Research on miRNAs has already been fruitful in the fields of oncology (Lu et al. 2005 ) and cardiology (Latronico and Condorelli 2009 ) but has limited traction in psychiatric investigations to date. Given the inherent limitations in accessing brain tissue in vivo, most human studies have utilized postmortem samples (Perkins et al. 2007; Beveridge et al. 2008; Beveridge et al. 2010; Mellios et al. 2009; Kim et al. 2010; Santarelli et al. 2011) or peripheral blood (Gardiner et al. 2011; Rong et al. 2011 ) to study miRNA expression. However, these approaches have methodological limitations: the study of postmortem brain tissue may be confounded by long postmortem interval and prior medication exposure (McCullumsmith and Meador-Woodruff 2011) ; alternately, peripheral blood may not closely reflect gene expression levels in the brain, especially since a subset of miRNAs may be brain-specific (Lagos-Quintana et al. 2002; Kim et al. 2004) .
Given the intimate relationship between brain and cerebrospinal fluid (CSF), the use of CSF-derived indices represents an intriguing new approach to identify the central nervous system (CNS) biomarkers. To date, very few studies have examined miRNA levels in CSF, in patients with Alzheimer's disease (Cogswell et al. 2008; Ghidoni et al. 2011) , B cell lymphoma of the CNS (Baraniskin et al. 2011) , and glioma (Baraniskin et al. 2012 ). To our knowledge, this approach has not yet been utilized in patients with psychiatric disorders. Importantly, no study has compared miRNA expression profiles in CSF and peripheral blood drawn from the same subjects, and recently developed miRNA expression microarrays have not been tested in CSF studies.
The ultimate goal of our study was to examine miRNA levels in CSF and peripheral blood in patients with schizophrenia; however, for this preliminary methodological report, we focus on the comparison in miRNA detection between CSF and peripheral blood using microarray technology. Given that gene expression patterns have shown to vary across different tissues, including brain and peripheral blood (Sullivan et al. 2006) , we hypothesized that a subset of CNS-relevant miRNAs will be detected exclusively or predominately in CSF compared to peripheral blood and that miRNA levels detected in CSF will be largely uncorrelated with levels derived from blood samples drawn from the same subjects. Data from this study can then be utilized to inform larger scale studies of the relationship between CSF miRNA and susceptibility for psychiatric illness.
Methods

Subjects
Patients with a diagnosis of schizophrenia, schizoaffective disorder, psychosis not otherwise specified (NOS), and long history of antipsychotic treatment were recruited from the outpatient department at The Zucker Hillside Hospital. Healthy controls were recruited from the general population via word of mouth, newspaper and internet advertisements, and poster flyers. Patients and healthy volunteers were excluded from participating in the study if they were prescribed with an anticoagulant, had a history of an organic brain disorder, had a positive urine toxicology test, or had clinically significant thrombocytopenia or coagulopathy based on results of CBC, PT, and APTT screening. Additionally, healthy volunteers were excluded if they had an Axis I diagnosis or if they had a first-degree relative with a known or suspected Axis I disorder, based on family history questionnaire. All subjects provided written informed consent to a protocol approved by the Institutional Review Board of the North Shore-Long Island Jewish Health System.
Procedure
In a single session, subjects underwent a blood draw followed by a lumbar puncture, performed using a standard technique with a 25 gauge, Whitacre point spinal needle. Two PAXgene whole blood tubes and 15-25 cc of CSF were obtained from each subject.
RNA Isolations from Human CSF and PaxGene Whole Blood
Total RNA was isolated from 7.5 ml of human CSF by Asuragen, Inc. according to a proprietary large-scale biofluid RNA isolation procedure. Because RNA concentration was not measurable, single-target TaqMan® miRNA qRT-PCR assays (Applied Biosystems) were tested using 150 CSF equivalents of unamplified RNA as a surrogate assessment of miRNA abundance.
Total RNA was isolated from PAXgene®-collected blood samples. The purity and quantity of total RNA samples were determined by absorbance readings at 260 and 280 nm using a NanoDrop ND-1000 UV spectrophotometer and fell within Asuragen's acceptable limits (A260/A280 greater than 1.6). The integrity of total RNA was qualified by Agilent Bioanalyzer 2100 capillary electrophoresis, and samples fell within Asuragen's acceptable limits (RIN greater than 6). In addition, single-target TaqMan® miRNA qRT-PCR assays (Applied Biosystems) were run using 1-ng input of unamplified RNA as a surrogate assessment of miRNA abundance.
TaqMan Megaplex Profiling (Human Array A)
Expression of 378 validated microRNAs (and three control transcripts) was assessed from each biofluid type for each of the subjects using microarray technology. For CSF, equal volume inputs of 11.5 CSF equivalents of the eluted RNA were used for Taqman Megaplex reverse transcription (RT) and pleamplication with Human Pools A. For RNA isolated from PAXgene-collected blood samples, a mass input of 100 ng was used as an input
The diluted preamplification product was loaded with an equal volume of 2× Universal Master Mix into each port of an ABI Human microRNA Array. All quantitative polymerase chain reaction (qPCR) steps were carried out according to the manufacturer's protocol. Detection was performed on a validated ABI 7900HT Real-time PCR instrument and Sequence Detection Software (SDS) 2.3 (Applied Biosystems).
qPCR Analysis
Five miRNAs were then chosen for validation using singletarget qPCR, based on the combination of prior reports in the literature and our Taqman Megaplex microarray results.
Single Target MicroRNA qRT-PCR Samples for single-target microRNA qRT-PCR analysis were processed by Asuragen, Inc. For each assay, target-specific reverse transcription and qPCR were performed according to the manufacturer's instructions using Applied Biosystems' TaqMan® MicroRNA Assays. Equal mass inputs of 1 ng total RNA were used from PAXgene blood samples. Equal volume inputs of 4 μl total RNA were used from CSF samples corresponding to 160 CSF equivalents of the original sample volume. Reverse transcription was carried out in triplicate reaction wells in incubation steps of 16°C for 30 min, 42°C for 30 min, and 85°C for 5 min. For PCR, following incubation at 95°C for 10 min, samples were amplified in 45 cycles of 95°C for 15 s, then 60°C for 30 s.
Megaplex MicroRNA qRT-PCR
Samples for Megaplex microRNA qRT-PCR analysis were processed by Asuragen, Inc. Equal volume inputs of 3 μl of the eluted CSF total RNA, corresponding to 120 CSF equivalents of the original sample volume, were used for TaqMan® Megaplex RT and preamplification with Human Pools A according to the manufacturer's (Applied Biosystems) protocol. For total RNA isolated from PaxGene blood samples, a mass input of 100 ng was used.
Single-target TaqMan® miRNA qPCR assays (Applied Biosystems) were run on a 20-fold dilution of the Megaplex RT/preamplification products according to Asuragen's standard operating procedure. Detection was performed on a validated ABI 7900HT Real-time PCR instrument and SDS 2.3 (Applied Biosystems). Raw data, mean cycle threshold (Ct) values, standard deviations, and threshold settings were exported from ABI's SDS software.
Statistical Analysis
Mean Ct values were normalized for each sample using mammalian U6 snRNA levels, due to its abundant detection in all CSF and peripheral blood samples in all eight subjects. The initial comparison of CSF and peripheral blood was conducted by counting the number of samples of each fluid type in which each miRNA was detected at a given Ct cutoff. MiRNAs detected exclusively in a single fluid type at even the most liberal Ct threshold were designated as such. CSF-predominant miRNAs were those miRNAs that were detected in more CSF samples than in whole blood samples, in addition to having lower overall normalized Ct values (ΔCt) in the CSF samples. Conversely, blood-predominant miRNAs were those that were detected in more whole blood samples than in CSF samples, in addition to having a lower normalized Ct count (ΔCt) in the whole blood samples. For miRNAs that were detected in both fluids in all eight subjects, we quantitatively compared expression levels across fluid type using Spearman's correlation.
Results
Overall Distribution of miRNAs in CSF and Whole Blood
Eight subjects participated in the study. Four subjects had no Axis I psychiatric disorder, two had a diagnosis of psychosis NOS, one had schizoaffective disorder, and one had schizophrenia. All subjects were male; mean age was 40.7 (SD 6.1).
A large number of miRNAs were detected in CSF and whole blood, even when using stringent thresholds for expression (Fig. 1) . Using a Ct cutoff of 40 or 35, a mean number of miRNAs detected were virtually identical in both fluid types. At Ct <30, a mean of 86 miRNAs were detected in whole blood, while 60 were detected on average in CSF (paired t01.19, df0 7, p00.27). Considering all samples, 248 distinct miRNAs were detected in CSF and 271 in whole blood samples.
Relationship Between miRNA Expression in CSF and Whole Blood
Based on microarray results, a substantial number (n095) of miRNAs were detected more robustly in CSF compared to Fig. 1 Number of miRNAs detected in cerebrospinal fluid and whole blood. Ct cycle threshold or number of amplification cycles required to reach a given threshold. Based on microarray analysis blood (Fig. 2) . Of those, 62 (65.3 %) miRNAs were classified as CSF-predominant (Suppl. Table 1 ) and 33 (34.7 %) were detected exclusively in CSF samples (Suppl. Table 2 ).
Given our focus on differential expression across fluid types, we used qPCR to validate the results for three miRNAs that showed clear CSF-blood expression differences in the microarray analysis: let 7b, mir 9, and mir 328. As shown in Suppl. Table 3 , qPCR results demonstrated statistically significant differences between blood and CSF expression levels in the same direction as the microarray results for each of these three miRNAs. We additionally used qPCR to examine two miRNAs of interest to neuroscience research, which were only weakly detected in a few CSF samples by microarray (mir-137 and mir-219-5p). While mir-137 was not detected by qPCR in either biofluid, we did obtain detected levels of mir-219-5p (mean Cts between 34 and 37) for all eight CSF samples, consistent with its prior characterization as a microRNA predominantly expressed in CNS.
Correlation Between miRNA Expression Profiles in CSF and Peripheral Blood
A total of 35 miRNAs were detected in both fluid types for all eight subjects. As observed in Fig. 3 , a histogram of the Spearman correlation coefficients comparing normalized CSF and whole blood values for each such miRNA shows that coefficients clustered around 0, indicating no systematic relationship between levels detected in the two fluids (Suppl. Table 4 ).
Discussion
The results of this study provide evidence that miRNAs can be successfully detected in CSF in healthy controls as well as in patients with schizophrenia spectrum disorders. Our data suggest that the miRNA detection in CSF provides independent information that is not captured by assays derived from peripheral blood. Specifically, we found that (1) some miRNAs were expressed in CSF, but not in whole blood; (2) some miRNAs were predominantly (though not solely) expressed in CSF; and (3) miRNA levels in CSF and blood samples were poorly correlated. These preliminary data suggest that the detection of miRNAs in CSF may be complementary to existing approaches for biomarker identification in the study of psychiatric disorders.
Our results are broadly consistent with a recent study by Sullivan et al. (2006) , who found that gene expression in whole blood is often not strongly correlated to gene expression in different postmortem brain tissues. However, that study did not specifically measure miRNA expression and did not examine CSF samples. A study comparing brain, CSF, and peripheral blood miRNA profiles in the same subjects would be ideal, but technical limitations render this study difficult to undertake, given the low feasibility of obtaining brain tissue from living subjects. To add more complexity, brain miRNA profiles may differ depending on the brain area being studied (Olsen et al. 2009) .
A growing literature has been started to link abnormal miRNA levels with schizophrenia in cross-sectional studies that used either postmortem brain tissue or peripheral blood (Perkins et al. 2007; Beveridge et al. 2008; Zhu et al. 2009; Moreau et al. 2011; Santarelli et al. 2011) . Most recently, mir-137 has attracted interest, since DNA sequence variation at this locus was found to be significantly associated in the largest genome-wide association study in schizophrenia (Ripke et al. 2011) . Our microarray data showed detection of low levels of mir-137 in three of the CSF samples; however, that finding was not confirmed by subsequent qPCR data. Despite the fact that a lumbar puncture is an invasive procedure, it is routinely used in clinical practice to aid in the diagnosis of illnesses such as meningitis and multiple sclerosis. However, to date, this procedure is not part of the standard diagnostic workup in patients with schizophrenia, due to the current lack of clinically useful information that can be obtained from it. On the other hand, it is likely that new technologies will facilitate the discovery of new biological markers in CSF, which could potentially impact clinical care. In this regard, miRNAs are emerging as potential useful biomarkers in various biofluids including CSF. The feasibility of performing a lumbar puncture in acutely psychotic patients was recently demonstrated by Kranaster et al. (2011) , who performed LPs in 155 first-episode schizophrenia patients and found that the procedure was well tolerated and had minimal adverse effects.
The exact origin of miRNAs found in CSF samples is unclear. However, Baraniskin et al. (2011 Baraniskin et al. ( , 2012 demonstrated the presence of extracellular miRNAs in centrifuged CSF samples in patients with primary CNS lymphoma, while Cogswell et al. (2008) used a similar approach to us by examining miRNAs in noncentrifuged CSF samples. The latter approach would probably detect a combination of extracellular miRNAs (as free-circulating miRNAs) and intracellular miRNAs released to the extracellular compartment after the lysis of the few red or white blood cells present in cerebrospinal fluid. Additionally, the presence of miRNAs inside exosomes has been recently demonstrated (Skog et al. 2008; Ramachandran and Palanisamy 2011) . To conclude, the fact that miRNAs are present in CSF in healthy volunteers rules out the hypothesis that miRNAs are present only in cases of pathological conditions of the CNS. In that regard, it's unlikely that miRNAs are just mere residues of cell death, and it is likely that miRNAs play an active role in posttranscriptional regulation across different areas of the brain.
The small sample size in our study prevented us from looking at differences between patients and healthy volunteers. Additionally, the degree of specificity of miRNA abnormalities in CSF in psychotic disorders is unclear. It is likely that miRNA abnormalities in CSF will not respect traditional DSM-IV diagnostic categories and will probably overlap across various CNS disorders, especially those that have been associated with neurodevelopmental abnormalities. Future studies should include the recruitment of antipsychotic treatment naïve patients as part of a randomized controlled trial, which could serve as the perfect platform to study illness-specific miRNA signatures, as well as possible changes in miRNA profiles that occur with antipsychotic exposure.
In summary, miRNAs are readily detected in the CSF and whole blood of patients with psychotic disorders, and certain miRNA are predominantly or exclusively expressed in the CSF. Future research studies are needed to determine the value of this approach in the study of psychiatric disorders.
